WHAT WE CLAIM IS:

1. A method for Cystic Fibrosis (CF) disease assessment in an individual, comprising detecting the presence or absence of outer membrane protein (OprF) in a sample from an individual.

2. The method according to claim 1, wherein the sample comprises airway surface liquid, sputa or combinations thereof.

3. A method for Cystic Fibrosis (CF) disease assessment in an individual, comprising detecting the presence or absence of outer membrane protein (OprF) antibodies in a sample from an individual.

4. The method according to claim 1, wherein the sample comprises blood, tissue, body fluids, or combinations thereof.

5. A method for treating anaerobic *Pseudomonas aeruginosa* biofilms in Cystic Fibrosis (CF) disease in an individual, comprising the steps of:

a. detecting the presence of outer membrane protein (OprF) in a sample from an individual; and

b. selecting a therapy regimen for the individual based on the presence of OprF;

wherein the anaerobic *Pseudomonas aeruginosa* biofilms in Cystic Fibrosis disease are treated by the therapy regimen.

6. The method according to claim 5, wherein the sample comprises airway surface liquid, sputa or combinations thereof.

7. A method for treating anaerobic *Pseudomonas aeruginosa* biofilms in Cystic Fibrosis (CF) disease in an individual, comprising the steps of:

a. detecting the presence of outer membrane protein (OprF) antibodies in a sample from an individual; and

b. selecting a therapy regimen for the individual based on the presence of OprF antibodies;

wherein the anaerobic *Pseudomonas aeruginosa* biofilms in Cystic Fibrosis disease are treated by the therapy regimen.

8. The method according to claim 5, wherein the sample comprises blood, tissue, body fluids, or combinations thereof.